Nucleome Therapeutics Advances First-in-Class Inflammation Resolution Antibody to Preclinical Development
Key Insights
Nucleome Therapeutics (search) has nominated NTP464 (search), a first-in-class monoclonal antibody agonist targeting a novel inflammation checkpoint (search) identified through the company's proprietary 3D genomics platform.
The therapeutic candidate demonstrated strong potency and selectivity in preclinical testing, showing ability to inhibit immune cell activation while promoting regulatory T cell function across multiple autoimmune diseases (search).
NTP464 (search) represents a paradigm shift from immune suppression to active inflammation resolution, with broad applicability across rheumatoid arthritis (search), systemic lupus erythematosus (search), and inflammatory bowel disease (search).
Nucleome Therapeutics (search) has nominated its first preclinical development candidate, NTP464 (search), a first-in-class monoclonal antibody agonist designed to actively resolve inflammation rather than simply suppress immune responses. The Oxford-based company's lead program targets a previously unrecognized inflammation checkpoint (search) discovered through its proprietary 3D genomics platform.
The therapeutic candidate emerged from Nucleome's breakthrough approach to understanding how genetic variation in the non-coding genome drives inflammatory disease. Using the company's Micro Capture-C (MCC) technology combined with machine learning and computational analysis, researchers identified a multi-cellular orchestrator of inflammation resolution that becomes dysregulated in autoimmune diseases (search) including rheumatoid arthritis (search), systemic lupus erythematosus (search), and inflammatory bowel disease (search).
Novel Mechanism of Action
NTP464 (search) targets a mechanism that helps restore immune balance in healthy individuals but becomes compromised in patients with autoimmune conditions. By analyzing how genetic variants associated with autoimmune disease alter three-dimensional interactions between regulatory elements and protein-coding genes, Nucleome uncovered this key regulator of inflammation resolution.
In preclinical testing, the monoclonal antibody agonist demonstrated strong potency, selectivity, and developability characteristics. Multiple in vitro assays showed NTP464 (search)'s ability to inhibit activation of B cells (search), T cells (search), and macrophages (search) while simultaneously promoting the suppressive activity of regulatory T cells (search). These combined effects support a novel therapeutic principle focused on actively resolving inflammation.
Platform Technology Breakthrough
The nomination represents a significant validation of Nucleome's 3D genomics approach to drug discovery. Dr. Mark Bodmer, CEO of Nucleome, emphasized the transformative potential of the company's technology: "Our lab-based technology, Micro Capture-C (MCC), combined with strategic deployment of machine learning and other computational methods has advanced genetics to an unprecedented level by deciphering patterns of gene regulation from the 3D architecture of the genome."
The company has created what it describes as "the most comprehensive physical map of molecular mechanisms in inflammatory disease," enabling the identification of causal drivers of disease in areas of high unmet medical need. This approach allows Nucleome to access previously untapped biology by linking disease-associated genetic variants with the genes they dysregulate.
Clinical Development Path
NTP464 (search) will now progress toward investigational new drug (IND)-enabling studies, marking a critical milestone for the company's pipeline. The program's broad applicability across major chronic inflammatory diseases positions it as a potential platform therapy for multiple autoimmune conditions.
The advancement comes as Nucleome strengthens its leadership team with the appointment of Dr. Michelle Morrow as Chief Scientific Officer. Dr. Morrow brings two decades of experience in drug discovery and development, including recent leadership roles at Avacta Therapeutics and F-star Therapeutics, where she guided oncology programs through candidate selection to IND approval.
Strategic Implications
The nomination of NTP464 (search) demonstrates the potential of Nucleome's approach to solve what the company describes as "the fundamental challenge of discovering molecular drivers of inflammatory disease from human genetics." By focusing on the non-coding genome, which comprises the vast majority of disease-associated genetic variants, the platform can identify novel targets and disease mechanisms that remain invisible to conventional approaches.
Dr. Morrow noted the significance of joining Nucleome at this pivotal stage: "Nucleome's ability to access previously untapped biology creates a powerful opportunity to deliver first-in-class immunomodulatory therapies, and I am eager to work with the team to advance these programmes towards the clinic."
The company's technology platform continues to generate insights across inflammatory diseases, with the potential to identify hundreds of novel targets and group patients by their common mechanistic disease drivers. This approach could enable more precise patient stratification and personalized treatment strategies in inflammatory disease management.